Workflow
华恒生物(688639) - 2024 Q4 - 年度业绩
AHBAHB(SH:688639)2025-02-25 08:10

Financial Performance - Total revenue for 2024 reached RMB 218,444.68 million, an increase of 12.70% compared to RMB 193,826.81 million in the previous year[4] - Operating profit decreased by 58.98% to RMB 20,954.85 million from RMB 51,090.33 million year-on-year[4] - Net profit attributable to shareholders of the parent company fell by 55.51% to RMB 19,978.17 million from RMB 44,906.15 million in the previous year[4] - Basic earnings per share decreased by 56.12% to RMB 0.86 from RMB 1.96 year-on-year[4] Assets and Equity - Total assets increased by 25.57% to RMB 498,524.26 million from RMB 397,023.81 million at the beginning of the period[4] - Shareholders' equity attributable to the parent company rose by 40.94% to RMB 257,492.09 million from RMB 182,697.12 million at the beginning of the period[4] - The company issued new shares, raising a net amount of RMB 684 million, contributing to the increase in equity[8] Profit Decline Factors - The decline in profits was primarily due to a decrease in the price of valine products and an increase in related expenses[7][8] - Weighted average return on equity decreased by 16.89 percentage points to 10.17% from 27.06% year-on-year[4] Market Response - The company is actively responding to market demand and competition, leading to sustained growth in product sales despite the profit decline[7]